|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
KR101867279B1
(ko)
|
2010-10-06 |
2018-06-15 |
리제너론 파아마슈티컬스, 인크. |
항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
|
|
HRP20180959T1
(hr)
|
2011-01-28 |
2018-07-27 |
Sanofi Biotechnology |
Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
CA2848201C
(en)
|
2011-09-16 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
|
ES2810003T3
(es)
|
2011-11-18 |
2021-03-08 |
Regeneron Pharma |
Micropartícula que contiene proteína terapéutica recubierta con polímero biodegradable para uso médico
|
|
MY164611A
(en)
|
2012-01-23 |
2018-01-30 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR092325A1
(es)
*
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
HUE064945T2
(hu)
|
2012-08-21 |
2024-04-28 |
Sanofi Biotechnology |
Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
|
|
US9592297B2
(en)
*
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US8883979B2
(en)
*
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
SI2892927T1
(sl)
|
2012-09-07 |
2018-10-30 |
Regeneron Pharmaceuticals,Inc |
Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R
|
|
BR112015008186A2
(pt)
*
|
2012-10-25 |
2017-09-19 |
Medimmune Llc |
formulação de um anticorpo estável e de baixa viscosidade
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI633891B
(zh)
|
2013-06-04 |
2018-09-01 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
|
|
CN111920954A
(zh)
|
2013-06-07 |
2020-11-13 |
再生元制药公司 |
通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
|
|
KR20160024916A
(ko)
*
|
2013-06-21 |
2016-03-07 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
|
|
TWI682781B
(zh)
|
2013-07-11 |
2020-01-21 |
美商再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
WO2015027154A2
(en)
|
2013-08-23 |
2015-02-26 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
CN106062003A
(zh)
|
2013-11-12 |
2016-10-26 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
RU2704999C2
(ru)
|
2014-02-28 |
2019-11-01 |
Ридженерон Фармасьютикалз, Инк. |
Способ лечения кожной инфекции путем введения антагониста il-4r
|
|
KR20170029613A
(ko)
|
2014-07-16 |
2017-03-15 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
AU2015310879A1
(en)
*
|
2014-09-03 |
2017-03-02 |
Medimmune Limited |
Stable anti-IL-4R-alpha antibody formulation
|
|
EP3218412A1
(en)
*
|
2014-11-14 |
2017-09-20 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
IL314925A
(en)
|
2015-08-18 |
2024-10-01 |
Regeneron Pharma |
Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
|
|
RU2753869C2
(ru)
|
2016-02-19 |
2021-08-24 |
Ридженерон Фармасьютикалз, Инк. |
Способы повышения эффективности вакцины путем введения антагониста il-4r
|
|
WO2017189805A1
(en)
|
2016-04-27 |
2017-11-02 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
|
CN113372446A
(zh)
|
2016-06-08 |
2021-09-10 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
EP4442323A3
(en)
|
2016-09-01 |
2025-01-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an il-4r antagonist
|
|
AU2017332732B2
(en)
|
2016-09-22 |
2024-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
|
|
MX2019006013A
(es)
|
2016-11-29 |
2019-10-14 |
Regeneron Pharma |
Composicion farmaceutica para evitar la adiccion a opioides.
|
|
TWI857389B
(zh)
|
2016-12-01 |
2024-10-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
EP3558347A1
(en)
|
2016-12-22 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
SG11201906852XA
(en)
|
2017-02-01 |
2019-08-27 |
Univ Yale |
Treatment of diuretic resistance
|
|
WO2018142514A1
(ja)
*
|
2017-02-01 |
2018-08-09 |
協和発酵キリン株式会社 |
ダルベポエチンを含む液体医薬組成物
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
SG11201909955XA
(en)
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
MX2020000228A
(es)
|
2017-07-06 |
2020-08-10 |
Regeneron Pharma |
Proceso de cultivo celular para producir una glicoproteina.
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
MA46269B1
(fr)
|
2017-08-18 |
2024-05-31 |
Regeneron Pharma |
Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
|
|
HUE064655T2
(hu)
|
2017-10-30 |
2024-04-28 |
Sanofi Biotechnology |
IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban
|
|
JP7321159B2
(ja)
|
2017-12-22 |
2023-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
薬剤生成物不純物を特性決定するためのシステム及び方法
|
|
SG11202006157VA
(en)
|
2018-01-05 |
2020-07-29 |
Corvidia Therapeutics Inc |
Methods for treating il-6 mediated inflammation without immunosuppression
|
|
BR112020013336A2
(pt)
|
2018-01-31 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
|
DK3768709T3
(da)
|
2018-03-19 |
2024-01-29 |
Regeneron Pharma |
Mikrochip-kapillærelektroforese-assays og reagenser
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
CN112153982A
(zh)
|
2018-05-13 |
2020-12-29 |
瑞泽恩制药公司 |
用于通过施用il-4r抑制剂治疗特应性皮炎的方法
|
|
CN112839956A
(zh)
|
2018-08-10 |
2021-05-25 |
瑞泽恩制药公司 |
安全有效治疗膝和/或髋疼痛的药物组合物
|
|
IL280880B2
(en)
|
2018-08-27 |
2025-04-01 |
Regeneron Pharma |
Using Raman Spectroscopy in Downstream Purification
|
|
BR112020026348A2
(pt)
|
2018-08-30 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
|
|
MY209127A
(en)
*
|
2018-10-18 |
2025-06-23 |
Merck Sharp & Dohme Llc |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
KR102330596B1
(ko)
|
2018-11-09 |
2021-11-26 |
아주대학교산학협력단 |
인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
FI3857237T3
(fi)
|
2019-01-16 |
2023-05-03 |
Regeneron Pharma |
Disulfidisidosten luonnehtimismenetelmiä
|
|
MX2021009851A
(es)
|
2019-02-18 |
2021-09-10 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos.
|
|
CA3129963A1
(en)
|
2019-03-06 |
2020-09-10 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
CN111686247B
(zh)
*
|
2019-03-13 |
2022-07-29 |
苏州康乃德生物医药有限公司 |
包含人白介素-4受体α的抗体的液体组合物
|
|
TWI861073B
(zh)
*
|
2019-03-21 |
2024-11-11 |
美商再生元醫藥公司 |
含有抗il-33抗體之穩定調配物
|
|
MX2021011141A
(es)
|
2019-03-21 |
2022-01-19 |
Regeneron Pharma |
Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
|
|
MA55807A
(fr)
|
2019-05-01 |
2022-03-09 |
Regeneron Pharma |
Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
MX2022000649A
(es)
|
2019-07-16 |
2022-06-08 |
Sanofi Biotechnology |
Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
|
|
AU2020326713A1
(en)
|
2019-08-05 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
EP4010001A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
CN120334439A
(zh)
|
2019-09-24 |
2025-07-18 |
里珍纳龙药品有限公司 |
用于色谱介质的使用和再生的系统及方法
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
CN119318636A
(zh)
|
2019-11-25 |
2025-01-17 |
里珍纳龙药品有限公司 |
使用非水性乳液的持续释放调配物
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
US11723974B2
(en)
|
2019-12-09 |
2023-08-15 |
Sanofi-Aventis Biotechnology |
Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
|
|
WO2021133776A1
(en)
|
2019-12-23 |
2021-07-01 |
Sanofi Biotechnology |
Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
|
|
EP4354145B1
(en)
|
2020-01-21 |
2025-09-17 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
CN114980926A
(zh)
*
|
2020-02-21 |
2022-08-30 |
江苏恒瑞医药股份有限公司 |
一种抗il-4r抗体药物组合物及其用途
|
|
MX2022011730A
(es)
|
2020-03-27 |
2022-10-13 |
Regeneron Pharma |
Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
|
|
US20250154267A2
(en)
|
2020-05-22 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
CN113797331A
(zh)
*
|
2020-06-16 |
2021-12-17 |
三生国健药业（上海）股份有限公司 |
一种稳定的抗IL-4Rα单克隆抗体液体制剂
|
|
AU2021305093A1
(en)
*
|
2020-07-08 |
2023-03-09 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-CTLA-4 antibodies
|
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
|
MX2023003942A
(es)
|
2020-10-05 |
2023-06-02 |
Sanofi Biotechnology |
Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
|
|
CA3191141A1
(en)
|
2020-11-25 |
2022-06-02 |
Hunter Chen |
Sustained release formulations using non-aqueous membrane emulsification
|
|
WO2022133135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
AU2022206434A1
(en)
|
2021-01-08 |
2023-08-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
IL305901A
(en)
|
2021-03-17 |
2023-11-01 |
Receptos Llc |
Methods for the treatment of atopic dermatitis using antibodies against IL-13
|
|
IL305731A
(en)
|
2021-03-26 |
2023-11-01 |
Regeneron Pharma |
Methods and systems for developing mixing protocols
|
|
TW202304507A
(zh)
*
|
2021-04-02 |
2023-02-01 |
美商再生元醫藥公司 |
含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
WO2023009437A1
(en)
|
2021-07-26 |
2023-02-02 |
Sanofi Biotechnology |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
|
MX2024002072A
(es)
|
2021-08-23 |
2024-05-20 |
Regeneron Pharma |
Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
|
|
US20240343815A1
(en)
*
|
2021-08-26 |
2024-10-17 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Pharmaceutical composition of anti-il4r antibody and use thereof
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CN118139881A
(zh)
*
|
2021-09-20 |
2024-06-04 |
瑞泽恩制药公司 |
控制抗体异质性的方法
|
|
JP2024540835A
(ja)
|
2021-10-07 |
2024-11-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨメーター較正及び補正
|
|
IL311245A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Systems and methods for pH modeling and control
|
|
JP2024539148A
(ja)
|
2021-10-20 |
2024-10-28 |
サノフィ・バイオテクノロジー |
Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法
|
|
CN118176167A
(zh)
|
2021-10-26 |
2024-06-11 |
瑞泽恩制药公司 |
用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法
|
|
US20250011408A1
(en)
|
2021-11-19 |
2025-01-09 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
CN118355034A
(zh)
|
2021-12-30 |
2024-07-16 |
瑞泽恩制药公司 |
施用il-4/il-13拮抗剂以减弱特应性进程的方法
|
|
CN119137473A
(zh)
|
2022-03-18 |
2024-12-13 |
里珍纳龙药品有限公司 |
分析多肽变体的方法及系统
|
|
EP4514849A1
(en)
|
2022-04-27 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
IL316264A
(en)
*
|
2022-05-02 |
2024-12-01 |
Regeneron Pharma |
Antibody formulations against interleukin-4 receptor (IL-4R)
|
|
WO2024011251A1
(en)
|
2022-07-08 |
2024-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
|
|
EP4580659A1
(en)
|
2022-08-29 |
2025-07-09 |
Sanofi Biotechnology |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
CN120187754A
(zh)
|
2022-11-01 |
2025-06-20 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗手足皮炎的方法
|
|
IL320670A
(en)
|
2022-11-23 |
2025-07-01 |
Regeneron Pharma |
Methods for enhancing bone growth by administering an IL-4R antagonist
|
|
EP4634659A1
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
WO2024178213A2
(en)
|
2023-02-22 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
WO2024197119A1
(en)
|
2023-03-22 |
2024-09-26 |
Sanofi Biotechnology |
Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
|
|
TW202502820A
(zh)
|
2023-03-27 |
2025-01-16 |
美商再生元醫藥公司 |
藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
|
|
WO2024199665A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
WO2024229136A1
(en)
|
2023-05-01 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
CN119215163A
(zh)
*
|
2023-06-30 |
2024-12-31 |
百奥泰生物制药股份有限公司 |
抗IL-4Rα抗体制剂及其制备方法和应用
|
|
WO2025017034A1
(en)
|
2023-07-17 |
2025-01-23 |
Formycon Ag |
Stable liquid antibody formulation for dupilumab
|
|
TW202528736A
(zh)
|
2023-09-08 |
2025-07-16 |
美商再生元醫藥公司 |
用於評估層析管柱完整性的方法及系統
|
|
US20250095773A1
(en)
|
2023-09-18 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
AR134008A1
(es)
|
2023-10-02 |
2025-11-26 |
Regeneron Pharma |
Sistema de seguridad de dispositivo de administración de fármaco
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
WO2025096932A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025116648A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형
|
|
WO2025116640A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 당류-프리 액상 제형
|
|
WO2025116637A1
(ko)
*
|
2023-12-01 |
2025-06-05 |
삼성바이오에피스 주식회사 |
항-IL-4Rα 항체의 안정한 액상 제형
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
EP4623903A1
(en)
|
2024-03-28 |
2025-10-01 |
Fresenius Kabi Deutschland GmbH |
Pharmaceutical composition comprising dupilumab
|
|
WO2025221640A1
(en)
|
2024-04-15 |
2025-10-23 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
CN118105485B
(zh)
*
|
2024-04-26 |
2024-09-03 |
湖南麦济生物技术有限公司 |
一种稳定的抗人IL-4Rα单克隆抗体制剂
|